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We tested the neuraminidase drug sensitivity of clade 
1 and clade 2 inﬂ  uenza A (H5N1). All viruses demonstrated 
similar sensitivity to zanamivir, but compared with the 2004 
clade 1 viruses, the Cambodian 2005 viruses were 6-fold 
less sensitive and the Indonesian clade 2 viruses were up 
to 30-fold less sensitive to oseltamivir.
T
wo different strains of highly pathogenic avian in-
ﬂ  uenza A (H5N1) have been circulating since 2003. 
Clade 1 has been found in Vietnam, Thailand, Cambodia, 
Lao People’s Democratic Republic, and Malaysia. Clade 2 
subsequently emerged and spread from People’s Republic 
of China to Indonesia, Europe, and Africa in 2004–2005. 
Because of its systemic availability, oseltamivir is the drug 
of choice for treating infected persons (1). 
The Study 
We tested the drug sensitivity of neuraminidases (NAs) 
(2) from inﬂ  uenza (H5N1) from chickens, ducks, geese, 
and quail1 from 2004 from Vietnam and Malaysia (pro-
vided by N. Long, Regional Animal Health Centre, Ho Chi 
Minh City, Vietnam; and S. Hassan, Veterinary Research   
Institute, Ipoh, Malaysia), from 2004–05 from Cambodia 
(provided by S. San, National Animal Health Production 
and Investigation Center, Phnom Penh, Cambodia), and 
from 2005 from Indonesia (provided by T. Usman). In the 
absence of a validated cell culture assay, the 50% inhibi-
tory concentration measured in the NA enzyme inhibition 
assay is used as the benchmark for measuring drug sensitiv-
ity (3).
Despite their origins in different countries and dif-
ferent avian species, all clade 1 and clade 2 viruses had a 
similar sensitivity to zanamivir as the reference inﬂ  uenza 
(H1N1) NA, (Table 1, Figure, panel A). However, sensi-
tivities of the NAs to oseltamivir (oseltamivir carboxylate) 
fell into 3 groups when compared to the NA of a reference 
human inﬂ  uenza (H1N1) strain (Table 1, Figure, panel B). 
The clade 1 isolates from 2004 were all more sensitive to 
oseltamivir than was the human inﬂ  uenza (H1N1) control, 
consistent with recent ﬁ  ndings of Rameix-Welti et al. (4). 
However, the NAs of our 2005 Cambodian viruses showed 
a 6- to 7-fold decrease speciﬁ  cally in oseltamivir sensitivity 
in comparison to our 2004 Cambodian isolates. These 2005 
isolates came from the same area as 1 of the more sensi-
tive 2004 isolates (Kandal), which suggested that at least 
regional evolution had occurred.
Of more concern was the third group. The NAs from 
all the clade 2 2005 Indonesian viruses demonstrated a 15- 
to 30-fold decrease in sensitivity speciﬁ  cally to oseltamivir 
compared with clade 1 viruses (Table 1, Figure, panel B). 
Govorkova et al. (5) also recently showed that the A/Tur-
key/15/2006 clade 2 virus was almost 60-fold less sensi-
tive to oseltamivir in a plaque reduction assay than was 
the clade 1 A/Vietnam/1203/2004 virus. Both these results 
and those of Rameix-Welti et al. (4) contrast to those re-
cently published by Hurt et al., who found no difference 
between the sensitivities of clade 1 and clade 2 isolates to 
oseltamivir in the enzyme assay (6), although many of the 
isolates were the same as  those tested here. The reason for 
the discrepancy is not known. The decrease in sensitivity 
is comparable to that conferred by the N294S recently de-
tected in Egypt (7), known to be selected for by oseltamivir 
treatment (8).
Although both drugs are based on the transition state 
analog of sialic acid, zanamivir has a single substitution of 
a guanidinium group at the 4′ position on the sugar ring, 
whereas oseltamivir has an amino group at the 4′ position 
and, more importantly, a bulky hydrophobic pentyl ether 
group replacing the glycerol side chain at the 6′ position. 
Reorientation of E276 in the active site is required to cre-
ate a hydrophobic pocket necessary to accommodate this 
pentyl ether group. Mutations that prevent this reorienta-
tion from occurring lead to high levels of speciﬁ  c osel-
tamivir resistance (H274Y, R292K). Decreased binding 
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1Isolates tested were the following: A/Mississippi/3/2001 wt, 
A/Mississippi/3/2001 H274Y; A/quail/Kelantan/6309/2004, A/
chicken/Kelantan/5858/2004, A/quail/Vietnam/007B/2004, A/duck/
Vietnam/007A/2004, A/chicken/Vietnam/0024/2004, A/chicken/
Vietnam/0023/2004 A/chicken/Vietnam/0018/2004, A/chicken/
Vietnam/0015/2004, A/chicken/Vietnam/0010/2004, A/chicken/
Vietnam/008/2004; A/chicken/Cambodia/Siem Reap/77B/2004, 
A/chicken/Cambodia/Siem Reap/76/2004, A/chicken/Cambodia/
Takeo/45/2004, A/chicken/Cambodia/Kandal/23/2004, A/chicken/
Cambodia/Pong Peay/1B/2004, A/chicken/Cambodia/Pong Peay/
1A/2004, A/goose/Cambodia/Kandal/2005, A/chicken/Cambodia/
Kandal/3/2005, A/chicken/Cambodia/Kandal/2/2005, A/chicken/
Cambodia/Kandal/1/2005, A/chicken/Indonesia/Wates/130/2005, 
A/chicken/Indonesia/Wates/126/2005, A/chicken/Indonesia/Wates/ 
83/2005, A/chicken/Indonesia/Wates/80/2005, A/chicken/Indonesia/ 
Wates/77/2005, A/chicken/Indonesia/Wates/1/2005.Oseltamivir Sensitivity of Inﬂ  uenza (H5N1)
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 9, September 2007  1355 
to oseltamivir can also be due to altered interactions with 
its 4-amino group (E119V) (9). We therefore tested sev-
eral viruses from each group for inhibition by a drug that 
shares the 4-amino substitution. The clade 1 and 2 viruses 
had similar sensitivity to 4-amino-Neu5Ac2en (Table 1, 
Figure, panel C), indicating the decreased binding to osel-
tamivir was speciﬁ  cally due to altered interactions around 
the 6-pentyl ether group, thus explaining why no altered 
binding to zanamivir was seen.
Because of the potentially important implications of 
our ﬁ  ndings for public health and stockpiling strategies, 
and because of the apparent discrepancy with the results 
of Hurt et al. (6), we retested 2 viruses from each group 
against an independent source of oseltamivir carboxylate 
(provided by Biota, Notting Hill, Victoria, Australia). We 
chose A/Indonesia/Wates/77/2005, which had a further 
slight decrease in sensitivity compared to other Indonesian 
isolates, as well as one that was in the same range as the 
remaining Indonesian isolates. Results shown in Table 2 
conﬁ  rm this decreased sensitivity of the clade 2 Indonesian 
isolates and a small further decrease in sensitivity of A/In-
donesia/Wates/77/2005.
Because we only had access to clade 2 isolates from 
Indonesia, we do not know whether this decreased sensitiv-
ity occurs only in the Indonesian clade 2 isolates or glob-
ally with all clade 2 isolates. Comparisons of the sequences 
in the public databases show several mutations in the stalk 
region, which vary between clade 1 and clade 2 NAs, but 1 
mutation in the globular head, H252Y, varies between all 
clade 1 and clade 2 isolates. A further 3-aa variation occurs 
between most clade 1 and clade 2 NAs, S343P, E387G, 
and G459S (N2 numbering), including the Indonesian 
isolates studied here. An additional V338M variation is 
found in most Indonesian isolates, including the ones stud-
ied here (sequences submitted by N. Komadina). Whether 
this additional variation confers this decreased oseltami-
vir sensitivity remains to be elucidated. The A/Indonesia/ 
Wates/77/2005 NA has an additional unique I117V varia-
tion, which is adjacent to one of the catalytic arginines, 
R118 (which would be consistent with a further effect on 
drug sensitivity to oseltamivir), and a slight decrease in 
sensitivity to zanamivir (2.3 nmol/L vs mean of 1.4 nmol/L 
for other Indonesian isolates).
Conclusions
We have shown here that, compared with clade 1 
isolates from 2004, some clade 1 Cambodian isolates and 
clade 2 Indonesian isolates from 2005 demonstrate reduced 
sensitivity to oseltamivir. Because none of the sequence 
variations in the public databases correlates with any mu-
tation known to confer oseltamivir resistance, and none of 
the variations are in the active site (10), this suggests that 
the decrease in sensitivities may be due to drift mutations 
rather than from exposure to oseltamivir. Recent results 
show that human isolates can also demonstrate decreased 
sensitivity to oseltamivir and zanamivir with drift muta-
tions in the NA remote from the active site (11). The dif-
ference in the amino acid at position 252 may partially ac-
count for the altered binding between the clade 1 and clade 
2 NAs as other researchers have suggested that the amino 
acid at position 252 can affect reorientation of the E276 
(4,10). In clade 1 NAs, this is normally H252, but all clade 
2 NAs have Y252. In the recently published N1 structure, 
although it is from a clade 1 inﬂ  uenza (H5N1) NA, the 
authors had mutated the NA to Y252 (10), which is also 
found in human NAs. The E276 in this structure does not 
Table 1. Mean IC50s of NA sensitivities in MUNANA*-based enzyme inhibition assay for influenza (H5N1) isolates from each region 
compared with a human influenza (H1N1) control and known resistant H274Y isolate† 
Isolate
Zanamivir,‡§
mean IC50, nmol/L
Oseltamivir,‡§
mean IC50, nmol/L
4-Amino-Neu5Ac2en,‡§  
mean IC50, μmol/L
Subtype H1N1
  A/Mississippi/3/2001 [2]¶ wt 1.18 (0.24) 2.16 (0.31) 1.12†
  A/Mississippi/3/2001 H274Y [4]¶ 1.41(0.26) 475.1 (344) 1.31†
Clade 1 subtype H5N1 2004
  Malaysia 2004 [2] 1.21 (0.13) 0.47 (0.07) 2.82 (0.77)
  Vietnam 2004 [8] 1.40 (0.44) 0.55 (0.26) 2.47 (0.42)
  Cambodia 2004 [6] 1.96 (0.56) 0.41 (0.24) 2.59 (0.15)
Clade 1 subtype H5N1 2005
  Cambodia 2005 [4] 1.53 (0.4) 2.88 (0.58) 2.56 (0.53)
Clade 2 subtype H5N1
  Indonesia 2005 [6] 1.42 (0.63) 11.45 (4.32) 2.00 (0.77)
*Sigma, Saint Louis, MO, USA. 
†IC50, drug concentration for 50% inhibition of enzyme activity; NA, neuraminidase; wt, wild type. 
‡Drugs provided by GlaxoSmithKline (Stevenage, Hertfordshire, UK). 
§Nos. in brackets indicate the nos. of isolates tested against zanamivir and oseltamivir in the same assay. Nineteen influenza (H5N1) isolates were 
retested in an independent assay against oseltamivir and 4-amino-Neu5Ac2en. Means for oseltamivir are the results of the 2 independent experiments. 
IC50s for each isolate were calculated by using the Sigmaplot nonlinear curve-fitting function (Systat Software Inc., London, UK). Values in parentheses 
are standard deviations for the means of the individual IC50s for the isolates in each group. 
¶Several plaques were tested from the A/Mississippi/3/2001 against zanamivir and oseltamivir, but only 1 plaque of each was tested against 4-amino-
Neu5Ac2en. DISPATCHES
1356  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 9, September 2007
appear to have undergone full reorientation, which could 
contribute the reduced oseltamivir binding found in to the 
Indonesian clade 2 isolates here. Testing the sensitivities of 
both NAs would provide valuable information on the role 
of H252. However, mutational analysis of the Indonesian 
and Cambodian isolates and structure determinations of the 
different NAs are necessary to fully understand the mecha-
nisms of altered binding. 
The speciﬁ  c decrease in sensitivity to oseltamivir of 
both 2005 Cambodian clade 1 and especially the Indone-
sian clade 2 inﬂ  uenza (H5N1) isolates is disturbing, espe-
cially because they maintain their pathogenicity and trans-
missibility in birds and are clearly pathogenic in humans, 
since Indonesia has the highest death rate from inﬂ  uenza 
(H5N1) infections of any country. This ﬁ  nding is in con-
trast to recent observations that mutations conferring zana-
mivir resistance in human strains have poor viability and 
are not genetically stable (12). Such a decrease in oseltami-
vir sensitivity could lead to suboptimal drug dosing in treat-
ing persons infected with these isolates, which is thought to 
facilitate selection of viruses with a high level of resistance 
(13). Several groups have reported the emergence of resis-
tant viruses in clade 1–infected inﬂ  uenza (H5N1) patients 
treated with oseltamivir and suggested that higher doses of 
oseltamivir may be needed (1,8). Because the clade 2 virus-
es studied here have a 15- to 30-fold decrease in sensitivity 
compared to the clade 1 viruses, this suggests the standard 
dosing of oseltamivir may be even less effective in treating 
clade 2 inﬂ  uenza (H5N1) A–infected patients. 
Many laboratories are developing rapid PCR sequenc-
ing methods for detecting the known mutation (H274Y) 
that confers high-level resistance in inﬂ  uenza  (H5N1). 
However, we have shown here the importance of pheno-
typic testing of isolates in an enzyme assay rather than 
just genotypic screening (14). Because the clade 2 virus is 
now spread through parts of Europe and Africa, continued 
global collaboration and phenotypic testing of drug sen-
sitivity of circulating highly pathogenic avian isolates for 
NA inhibitor sensitivity are critical. This knowledge is es-
sential for developing appropriate management strategies 
for pandemic planning. No altered sensitivity to zanamivir 
occurred, which further supports the hypothesis of mini-
malist drug design (15) and of maintaining the inhibitor as 
close as possible to the natural substrate to minimize the 
emergence of resistance. Our results suggest that zanamivir 
may also play an important role in pandemic stockpiles.
Parts of this work were funded by the Australian Department 
of Agriculture, Fisheries and Forestry; and a National Health and 
Medical Research Council of Australia grant no. 414400.
Figure. Sensitivity of clade 1 and clade 2 inﬂ  uenza  A  (H5N1) 
viruses to zanamivir, oseltamivir, and 4-amino-Neu5Ac2en in a 
MUNANA-based enzyme inhibition assay (Sigma, Saint Louis, 
MO, USA). Viruses were grown in allantoic ﬂ  uid and irradiated for 
testing sensitivities of their neuraminidases. Plots are the mean 
values for inhibition of enzyme activity for each drug concentration 
of all isolates from that country and year; bars represent standard 
deviations of values for all isolates from that group. A) Sensitivity 
to zanamivir; B) sensitivity to oseltamivir; C) sensitivity to 4-amino-
Neu5Ac2en. Oseltamivir Sensitivity of Inﬂ  uenza (H5N1)
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Table 2. Mean IC50s of isolates from each group against alternative source of oseltamivir*† 
Virus Oseltamivir, IC50, nmol/L
A/Mississippi/3/2001 wt 3.2 (2.1)
A/Chicken/Vietnam/008/2004 0.7 (0.4)
A/Chicken/Cambodia/Kandal/23/2004 0.4 (0.2)
A/Goose/Cambodia/Kandal/2005 4.2 (0.5)
A/Chicken/Cambodia/Kandal/3/2005 4.8 (0.5)
A/Chicken/Indonesia/Wates/77/2005 25.6 (2.5)
A/Chicken/Indonesia/Wates/126/2005 14.7 (2.3)
*IC50, drug concentration for 50% inhibition of enzyme activity; wt, wild type. 
†Isolates were tested in duplicate in 2 separate assays. IC50s and standard errors (in parentheses) were calculated by using the nonlinear curve-fitting 
function in Sigmaplot (Systat Software Inc., London, UK).